The 70% (21/30) of tumours with TERT expression held at least one pathogenic alteration at TERT promoter, being promoter methylation more frequent than the presence of promoter mutations (53.3%, 16/30 and 33.3%, 10/30, respectively) (Figure 2C and Figure S3A). This evidence concerns the gene TERT and neoplasm.